Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index; 18 of the 30 sources its claims cite were checked for support.
Abstract
Microphysiological systems (MPS) and Organs-on-Chips (OoCs) hold significant potential for replicating complex human biological processes in vitro. However, their widespread adoption by industry and regulatory bodies depends on effective qualification to demonstrate that these models are fit for purpose. Many models developed in academia are not initially designed with qualification in mind, which limits their future implementation in end-user settings. Here, we explore to which extent aspects of qualification can already be performed during early development stages of MPS and OoCs. Through a case study of our blood-perfused Vessel-on-Chip model, we emphasize key elements such as defining a clear context-of-use, establishing relevant readouts, ensuring model robustness, and addressing inherent limitations. By considering qualification early in development, researchers can streamline the progression of MPS and OoCs, facilitating their adoption in biomedical, pharmaceutical, and toxicological research. In addition, all in vitro methods must be independent of animal-derived materials to be considered fully fit for purpose. Ultimately, early qualification efforts can enhance the availability, reliability, and regulatory as well as ethical acceptance of these emerging New Approach Methodologies.
Overview
CoChat Summary
TL;DR
This case study argues that aspects of regulatory qualification can and should be considered during early development of microphysiological systems and Organs-on-Chips, using a blood-perfused Vessel-on-Chip model of microthrombosis as an example. It shows that readouts and robustness were already partly addressed, while context-of-use, limitations, and animal-derived materials remain key gaps for future fit-for-purpose qualification.
Key findings
- Early qualification is feasible in academic MPS/OoC development: the Vessel-on-Chip already had relevant readouts and robustness checks, but its context-of-use was initially broad and implicit rather than clearly defined.
- The model captures microthrombosis by platelet aggregation and fibrin formation on activated endothelium; positive controls used 10 ng/mL TNF-α, negative controls used EGM-2 medium, and anti-CD41 plus fluorescent fibrinogen were added 10 min before blood perfusion.
- Robustness testing showed similar increased platelet and fibrin deposition across different endothelial cell sources with 10 ng/mL TNF-α; blood-donor variability was managed with thresholds of <2% culture area covered for negative controls and >4% coverage for positive controls before including donor data.
- The model’s stated limitations include being endothelial-only, assessing only acute thrombosis with a maximum perfusion time of 30 minutes, and PDMS absorption of small hydrophobic molecules; animal-derived components such as heparin, antibodies, and rat tail collagen must be replaced for the model to be considered fully fit for purpose.
Methods
- Case study mapping key qualification aspects—context-of-use, readouts, robustness, and limitations—onto prior development and application of a blood-perfused Vessel-on-Chip model.
- The device is a PDMS microfluidic chip with four rectangular channels (14 mm × 300 μm × 50 μm; length × width × height) bonded to a PDMS-coated microscope slide; HUVECs or hiPSC-ECs were seeded at 15×10⁶ cells/ml in two steps to form an endothelial monolayer.
- After endothelial treatment, recalcified human whole blood was perfused through the channels; platelet aggregation and fibrin deposition were visualized and quantified by fluorescence microscopy using fluorescently labelled anti-CD41 antibodies and fibrinogen.
Limitations
- Paper-stated: the model lacks a well-defined context-of-use at early development; it is limited to endothelial cells and cannot account for tissue-resident immune cells or organ–organ interactions; it can only assess acute thrombotic effects with a maximum perfusion time of 30 minutes; PDMS absorbs small hydrophobic molecules; and animal-derived components introduce variability and prevent the model from being fully fit for purpose.
- Paper-stated: donor age or gender could not be accessed due to donor service regulations, limiting prediction of donor-related variability.
- Evident from the text: qualification aspects were mostly addressed implicitly and characterization data were split across publications; full qualification would require more data, standardization, and multi-stakeholder collaboration, and the SOP for fabrication and readout was still being drafted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
15 Valid · 5 Not valid · 7 Not checked · 37 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Based on this proof-of-concept, we engaged in collaborative studies to apply the model in more defined CoUs, e.g., in tracking thrombosis as an unwanted side-effect of immunosuppressive monoclonal antibody drug candidates (Barrile et al., 2018), or novel therapeutic chimeric antigen receptor (CAR-)T cells.”
§ Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip > Introduction > Qualification of the blood-perfused Vessel-on-Chip model
What the sources say
- Supportedcites Barrile et al., 2018 source
The paper’s opening summary (p. 1) describes using a Vessel-Chip to assess thrombosis caused by Hu5c8, a monoclonal antibody intended to treat autoimmune disorders. The study description (p. 2) also says the chip was used to compare Hu5c8 with a modified antibody for prothrombotic effects. The citing authors’ description of the work as collaborative is their own framing. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Stakeholders in the field of OoC identified qualification as an area of high importance for training of early developers of OoC models (Moruzzi et al., 2023).”
§ Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip > Introduction
What the sources say
- Partly supportedcites Moruzzi et al., 2023 sourceExperimental — accuracy not yet measured
Section 3.2 reports that 64% of respondents rated qualification of OoC models very important for development of the field. The Discussion distinguishes qualification from training priorities and identifies qualification training as a need for technicians and scientist end-users, not specifically early developers of OoC models. The claim therefore conflates a high-priority field concern with a training priority for that group. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, both commercial and in-house cell batches often show some degree of heterogeneity in cell type or phenotype (Mertz et al., 2018).”
§ Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip > Introduction > Qualification of the blood-perfused Vessel-on-Chip model
What the sources say
- Partly supportedcites Mertz et al., 2018 sourceExperimental — accuracy not yet measured
Section 2.5 (page unavailable) describes phenotypic heterogeneity in cultured primary cells and in some cell lines. It does not distinguish commercial from in-house cell batches or establish how often batches from either source are heterogeneous. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, animal-derived antibodies in our workflow can be substituted, as demonstrated by the use of chemical cell tracker DiOC6 to stain platelets within blood, achieving comparable readouts to antibody-based approaches (Westein et al., 2012).”
§ Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip > Discussion
What the sources say
- Partly supportedcites Westein et al., 2012 sourceExperimental — accuracy not yet measured
The ‘New detection technologies in combination with microfluidic devices’ section identifies DiOC6 and fluorescently labeled antibodies as alternative ways to detect platelets; Table I in ‘Up-scaling the throughput of blood samples’ lists blood-flow assays using DiOC6. The paper does not report a direct comparison or establish that DiOC6 achieves comparable readouts to antibody-based approaches. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For the endothelial cell cultures in our model, commonly used supplements like heparin, which is animal derived, can be replaced with biochemically synthesized alternatives (Douaisi et al., 2024).”
§ Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip > Discussion
What the sources say
- Partly supportedcites Douaisi et al., 2024 sourceExperimental — accuracy not yet measured
The Abstract reports synthesis of animal-free heparin with chemical and biological properties similar to porcine heparin, supporting the existence of a biochemically synthesized alternative. The paper addresses heparin as an anticoagulant, however, and does not establish that its product can replace heparin as an endothelial-cell culture supplement. The cited passages have no page numbers in our copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
11 more claims · 1 with their cited sources checked
Create a free account to see all 64 claims and every source verdict.
- Probably not a substantial claim. 39
- It may state two separate claims as one. 20
Citations
Cites
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Small molecule absorption by PDMS in the context of drug response bioassays
van Meer, B. J., de Vries, H., Firth, K. S. A., van Weerd, J., Tertoolen, L. G. J., Karperien, H. B. J., Jonkheijm, P., Denning, C., IJzerman, A. P., & Mummery, C. L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.062 · Cited by 502
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300313 · Cited by 371
Jain, A., Barrile, R., van der Meer, A., Mammoto, A., Mammoto, T., De Ceunynck, K., Aisiku, O., Otieno, M., Louden, C., Hamilton, G., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.742 · Cited by 325
Self-citationTissue-resident immune cells in humans
Gray, J. I., & Farber, D. L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-112809 · Cited by 181
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Standardisation needs for organ on chip devices
Piergiovanni, M., Leite, S. B., Corvi, R., & Whelan, M. (2021) · Lab on a Chip · doi:10.1039/d1lc00241d · Cited by 155
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium
Jain, A., van der Meer, A. D., Papa, A.-L., Barrile, R., Lai, A., Schlechter, B. L., Otieno, M. A., Louden, C. S., Hamilton, G. A., Michelson, A. D., et al. (2016) · Biomedical Microdevices · doi:10.1007/s10544-016-0095-6 · Cited by 148
Barrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138
Tissue factor in infection and severe inflammation
Levi, M., van der Poll, T., & ten Cate, H. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-933338 · Cited by 126
ISSCR standards for the use of human stem cells in basic research
Ludwig, T. E., Andrews, P. W., Barbaric, I., Benvenisty, N., Bhattacharyya, A., Crook, J. M., Daheron, L. M., Draper, J. S., Healy, L. E., Huch, M., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.08.003 · Cited by 126
Organ-on-chip in development: Towards a roadmap for organs-on-chip
partners, T. O., Mastrangeli, M., Millet, S., & van den Eijnden-van Raaij, J. (2019) · ALTEX · doi:10.14573/altex.1908271 · Cited by 114
Guidance document on Good cell and tissue culture practice 2.0 (GCCP 2.0)
Pamies, D. (2021) · ALTEX · doi:10.14573/altex.2111011 · Cited by 100
Towards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Halaidych, O. V., Freund, C. M. A. H., van den Hil, F. E., Salvatori, D. C. F., Riminucci, M., Mummery, C. L., & Orlova, V. V. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.012 · Cited by 80
Peters, M. F., Choy, A. L., Pin, C., Leishman, D. J., Moisan, A., Ewart, L., Guzzie-Peck, P. J., Sura, R., Keller, D. A., Scott, C. W., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc01107b · Cited by 76
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
Ainslie, G. R., Davis, M., Ewart, L., Lieberman, L. A., Rowlands, D. J., Thorley, A. J., Yoder, G., & Ryan, A. M. (2019) · Lab on a Chip · doi:10.1039/c9lc00492k · Cited by 65
Monitoring in vitro thrombus formation with novel microfluidic devices
Westein, E., de Witt, S., Lamers, M., Cosemans, J. M. E. M., & Heemskerk, J. W. M. (2012) · Platelets · doi:10.3109/09537104.2012.709653 · Cited by 54
Hardwick, R. N., Betts, C. J., Whritenour, J., Sura, R., Thamsen, M., Kaufman, E. H., & Fabre, K. (2020) · Lab on a Chip · doi:10.1039/c9lc00519f · Cited by 48
Phillips, J. A., Grandhi, T. S. P., Davis, M., Gautier, J.-C., Hariparsad, N., Keller, D., Sura, R., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00925f · Cited by 38
Engineering cell heterogeneity into organs-on-a-chip
Mertz, D. R., Ahmed, T., & Takayama, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00413g · Cited by 33
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300131 · Cited by 33
Douaisi, M., Paskaleva, E. E., Fu, L., Grover, N., McManaman, C. L., Varghese, S., Brodfuehrer, P. R., Gibson, J. M., de Joode, I., Xia, K., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315586121 · Cited by 31
Manz, X. D., Albers, H. J., Symersky, P., Aman, J., van der Meer, A. D., Bogaard, H. J., & Szulcek, R. (2020) · Journal of Visualized Experiments · doi:10.3791/61068 · Cited by 30
Self-citationWeber, T., Bajramovic, J., & Oredsson, S. (2024) · MethodsX · doi:10.1016/j.mex.2024.102592 · Cited by 26
Sønstevold, L., Czerkies, M., Escobedo-Cousin, E., Blonski, S., & Vereshchagina, E. (2023) · Micromachines · doi:10.3390/mi14030532 · Cited by 25
Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
Pointon, A., Maher, J. M., Davis, M., Baker, T. K., Cichocki, J. A., Ramsden, D., Hale, C. M., Kolaja, K. L., Lévesque, P., Sura, R., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01040e · Cited by 22
Industry Adoption of Organoids and Organs‐on‐Chip Technology: Toward a Paradox of Choice
Homan, K. A. (2023) · Advanced Biology · doi:10.1002/adbi.202200334 · Cited by 22
Gandhi, P. S., Živkovic, M., Østergaard, H., Bonde, A. C., Elm, T., Løvgreen, M. N., Schluckebier, G., Johansson, E., Olsen, O. H., Olsen, E. H. N., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00418-4 · Cited by 22
Albers, H. J., Passier, R. C., van den Berg, A., & van der Meer, A. D. (2019) · Micromachines · doi:10.3390/mi10110781 · Cited by 18
Self-citationTraining the next generation of researchers in the organ-on-chip field
Moruzzi, A., Shroff, T., Keller, S., Loskill, P., & Cipriano, M. (2023) · Education Sciences · doi:10.3390/educsci13020144 · Cited by 12
Heads on! Designing a qualification framework for organ-on-chip
(2024) · ALTEX · doi:10.14573/altex.2401231 · Cited by 5
Research works printed but not linked: 5
- 2024, Innovative science and technology approaches for new drugs (ISTAND) pilot program, FDA
- 2016, Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches
- 2017, FDA’s predictive toxicology roadmap, U. S. Food Drug Adm.
- 2020, FDA’s Qualification process for drug development tools, U. S. Food Drug Adm.
- Leite, 2021, Resources for Organ-on-Chip validation and qualification - EUROoCS RAB’
Cited by
Fetal bovine serum: how to leave it behind in the pursuit of more reliable science
Weber, T., Malakpour‐Permlid, A., Chary, A., D’Alessandro, V., Haut, L., Seufert, S., Wenzel, E. V., Hickman, J. J., Bieback, K., Wiest, J., et al. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1612903 · Cited by 53
Meng, H., & Day, P. J. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1776815 · Cited by 11
“Other innovative and applicable technologies include omics-based profiling, high-throughput screening, 3D bioprinting and organ-on-a-chip systems, etc. (Combe et al., 2024; Baltazar et al., 2023; Weener et al., 2024; Ali et al., 2024).”
Application of 3D Cell Culture Techniques in Nanotoxicology: How Far Are We?
Shakeri, R., Mirjalili, S. Z., Karakuş, C. Ö., & Safavi, M. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11052-x · Cited by 3
“[49]”
Cheong, S. Y., Liew, T. I. Z., Wong, C. K., Teng, X. X., Cha, X. Y., Ng, N. C., Wong, R. S.-Y., & Goh, B. H. (2026) · Biomedical Microdevices · doi:10.1007/s10544-026-00849-3 · Cited by 2
“Qualification should also demonstrate stability during the intended experimental window and reproducibility across independent experiments and, where relevant, donors or cell batches (Araújo-Gomes et al. 2026; Pamies et al. 2024 ; Weener et al. 2024 ).”
Catastrophic Antiphospholipid Syndrome
Gris, J., Chéa, M., & Pérez‐Martin, A. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2765-9663
Metadata
- Authors
- Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D.
- Affiliations
- University of Twente (NL)
- Corresponding author
- Weener, Huub J.
- Venue
- Frontiers in Toxicology
- Publisher
- Frontiers Media SA
- Published
- 2024-12-06
- Volume
- 6
- Pages
- 1513002-1513002
- ISSN
- 2673-3080 (ISSN-L)
- PMC
- PMC11659250
- OpenAlex
- W4405122965
- Semantic Scholar
- 71028cd3c3c1e221071d1e09fa74b1d01bde4733
- Cited by
- 10
- References
- 38
- Citations by year
- 2026: 9 · 2025: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Twente Research Information (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Innovative Medicines Initiative (853988)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- microphysiological systems, organ-on-a-chip, microvascular thrombosis, regulatory qualification, context of use, model robustness, readout, animal-derived materials, new approach methodologies, in vitro model, toxicology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.